Fractyl Health Inc. has announced positive results from the 3-month REVEAL-1 Cohort data of its REMAIN-1 pivotal study, focusing on Revita®, a potential weight maintenance therapy. The study suggests that Revita may aid in maintaining or furthering weight loss after discontinuation of GLP-1 drugs. In this cohort, 12 out of 13 participants maintained or lost weight, with six losing additional weight post-GLP-1 therapy. The median weight remained stable, in contrast to the typical 5-6% weight regain expected after stopping GLP-1 therapy. The treatment demonstrated an excellent tolerability profile, with infrequent, mild, and transient treatment-emergent adverse effects. Fractyl Health is preparing for two key upcoming data readouts: the randomized Midpoint Cohort data expected in Q3 2025 and the 6-month primary endpoint data from the Pivotal Cohort anticipated in H2 2026. These results will further evaluate Revita's potential safety and efficacy in post-GLP-1 weight maintenance.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.